Clinical variants and staging of Kaposi's sarcoma

Abstract

Kaposi's sarcoma (KS) in the acquired immunodeficiency syndrome (AIDS) is a new and aggressive presentation of a previously rare malignancy. Variation in the clinical course of this disease and its response to treatment suggest that clinical or immunologic parameters may be important in its prognosis. A review of the clinical staging systems for epidemic (AIDS-related) KS (EKS) suggests an improved survival with lower tumor stages, the lack of prior opportunistic infections, and the absence of systemic symptoms. In addition, retrospective analysis of 16 immune parameters for their prognostic value showed that total CD4 (T4) cell numbers and the CD4:CD8 ratio correlated most closely with survival. Response to treatment with recombinant alpha-interferon did not correlate with tumor stage, but was more frequent in patients without systemic symptoms or prior opportunistic infections. Several studies suggest that treatment response is associated with a greater degree of intact T cell function. These findings point out the importance of cellular immunity in the prognosis of patients with EKS.